Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of neoadjuvant FOLFOXIRI versus CAPOX/FOLFOX with chemoradiotherapy in high-risk locally advanced rectal cancer
NL-OMON59467Phase 3Recruiting
- Sponsor
- Catharina Ziekenhuis
- Start
- Mar 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluorouracil, oxaliplatin, irinotecan and capecitabine in rectal cancer, sponsored by Catharina Ziekenhuis. Primary endpoints: Pathological complete response post-operatively and Sustained clinical complete response at 1 year. Started Mar 2026; status: recruiting.
02
Drugs
fluorouraciloxaliplatinirinotecancapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NL-OMON59467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59467.